Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 3,157-3,168 of 4,306
Behavioral study icon
Not recruitingISRCTN22197467

Well-Track: Wearable activity/sleep tracker for health & wellbeing

This study is looking at a support or therapy approach for people with First or early psychosis, Mental and Behavioural Disorders, or Psychosis. Participants take part in the program or support approach and complete follow-up assessments.

In United Kingdom
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaOtherOver 18 Years
Countries
United Kingdom
Sponsor
Northamptonshire Healthcare NHS Foundation Trust
Condition
Schizophrenia
Drug study icon
TerminatedEUCTR 2005-003475-20

A Randomized, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of Bifeprunox in the Treatment of Elderly Subjects with Psychosis and Behavioural Disturbances Associated wit...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.
Countries
Czechia, Estonia
Sponsor
Solvay Pharmaceuticals, Inc
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2006-005585-40

A randomized, parallel group, multiple dose, 6 week study to evaluate safety, tolerability, and pharmacokinetics of asenapine in elderly subjects with psychosis.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic
Why is this study shown?

This study is directly about Schizophrenia.

Schizophrenia, BipolarityDrug
Countries
Czechia
Sponsor
NV Organon
Condition
Schizophrenia, Bipolarity
Drug study icon
CompletedEUCTR 2016-003512-12

An Open-Label Extension Study to Examine the Safety and Tolerability of Pimavanserin in the Treatment of Parkinson’s Disease Psychosis

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In France
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
France
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
Drug study icon
TerminatedEUCTR 2014-003834-21

Effectiveness of penfluridol (oral long acting neuroleptic) as compared to second generation oral neuroleptics in psychotic disorder patients: an open label randomized controlled trial.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Netherlands
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Netherlands
Sponsor
Erasmus Medical Center Rotterdam
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2007-000307-15

Safety and Efficacy of Melperone in the Treatment of Patients with Psychosis Associated with Parkinson's Disease.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Italy
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Italy
Sponsor
OVATION PHARMACEUTICALS INC
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2018-002267-25

SAFETY AND EFFICACY OF OLANZAPINE TREATMENT IN PSYCHOSIS: EFFECT OF GENETIC AND EPIGENETIC FACTORS – COVARIATES OF TREATMENT RESPONSE

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Czechia
Sponsor
Fakultní nemocnice Brno
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2010-022463-35

The Benefit of Minocycline on Negative Symptoms in Psychosis: Extent and Mechanisms

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
United Kingdom
Sponsor
Manchester Mental Health and Social Care Trust
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2010-022307-22

The Bergen Psychosis Project 2

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Austria, Norway
Sponsor
Haukeland University Hospital, Division of Psychiatry
Condition
Schizophrenia
Other study type icon
Not recruitingISRCTN73679874

Brixton Early Psychosis Project

This study is looking at care and outcomes for people with Schizophrenia and other psychoses, Mental and Behavioural Disorders, or Schizophrenia. Taking part may give some people access to 1, but direct benefit is not guaranteed.

In United Kingdom
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaOther
Countries
United Kingdom
Sponsor
NHS R&D Regional Programme Register - Department of Health (UK)
Condition
Schizophrenia
Drug study icon
Not recruitingISRCTN16262847

Eye movement desensitization and reprocessing therapy in early psychosis

This study is testing a medication approach for people with Schizophrenia, schizotypal and delusional disorders or Mental and Behavioural Disorders. Participants receive a study treatment and complete follow-up visits and assessments.

In United Kingdom
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaOther
Countries
United Kingdom
Sponsor
Lancashire Care NHS Foundation Trust
Condition
Schizophrenia
Drug study icon
Not recruitingISRCTN48799530

How does oxytocin affect brain functioning in people at high risk of developing psychosis?

This study is looking at whether This is a randomised, double-blind, 40 IU intranasal oxytocin versus placebo single-dose challenge with a crossover design (1-week washout) can help people with Schizophrenia, schizotypal and delusional disorders or Mental and Behavioural Disorders. Participants receive a study treatment and complete follow-up visits and assessments.

In United Kingdom
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaOther
Countries
United Kingdom
Sponsor
King's College London
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.